What's on the Horizon in Metastatic Urothelial Carcinoma

July 1, 2020
Kristie L. Kahl
Kristie L. Kahl

Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.

In this episode of the “CURE Talks Cancer” podcast we spoke with two experts on the treatment landscape of metastatic urothelial carcinoma and what patients have to look forward to.

The treatment paradigm for metastatic urothelial carcinoma has shifted significantly over the last decade with immunotherapy and precision medicine.

In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Elizabeth Plimack, chief of the Division of Genitourinary Medical Oncology at Fox Chase Cancer Center, Temple Health, and Dr. Sumanta (Monty) Pal, from City of Hope Comprehensive Cancer Center, about metastatic urothelial.

The experts discussed the treatment landscape for this disease, how patients can learn more about their options and what they have to look forward to on the horizon.

Related Content:

Podcasts
Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine
Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research
FDA Approvals from February 2024